Statin Therapy May Ease Symptoms of Lymphocytic Colitis
A physician reports that taking pravastatin for high cholesterol unexpectedly improved his long-standing lymphocytic colitis. Research suggests statins have anti-inflammatory effects and may lower colorectal cancer risk in IBD patients. The case highlights how individual responses to medication can reveal new therapeutic possibilities.
The author, a physician who had managed lymphocytic colitis for two decades through dietary restrictions, began taking pravastatin for elevated cholesterol. He noticed his bowel symptoms improved markedly, allowing him to reintroduce foods like chocolate that previously triggered episodes. Testing the connection by pausing and resuming the drug produced corresponding symptom changes, suggesting a genuine medication effect.
Scientific literature offers plausible support for this observation. A 2023 systematic review of 21 preclinical studies found statins reduced disease activity and inflammatory markers in animal colitis models. Additional research has examined whether statins lower colorectal cancer risk in IBD patients, pointing toward broader anti-inflammatory properties beyond cholesterol management.
This case report could encourage clinicians to consider statins as a potential adjunct therapy for patients with lymphocytic colitis, particularly those who also need cholesterol management. If larger studies confirm these effects, it may open new treatment avenues for a condition with limited options. However, individual anecdotes are not definitive evidence, and patients should not alter medications without medical guidance. The story may also prompt researchers to design formal trials investigating statins' anti-inflammatory role in colitis.